Knight Cancer Group Appointed Leadership Board

The Portland-based organization has named its inaugural executive team and board of directors.

Updated on Sept. 24, 2026 in People

Knight Cancer Group Appointed Leadership Board

Live Poll

Should medical research organizations be managed by independent, self-governing nonprofit boards?

Oregon Health & Science University's Knight Cancer Group has officially appointed its inaugural board of directors and executive leadership team. This announcement follows the organization's approval as a self-governing nonprofit in June 2026.

Why it matters

The Knight Cancer Group holds authority over the Knight Cancer Institute's strategy, budgets, and leadership. It serves to govern the care delivery model and oversee all cancer services provided by OHSU.

The new board of directors consists of nine members tasked with overseeing a group backed by a $2 billion commitment from Phil and Penny Knight. The nonprofit structure grants the group full authority over institutional budgets and strategy.

The players

Brian Druker

He serves as the president of the Knight Cancer Group and is a prominent leader in cancer research.

Joel Helmke

He serves as the CEO of the Knight Cancer Group and oversees the organizational strategy.

Shivaani Kummar

She serves as the director of the Knight Cancer Institute and chief scientific and academic officer.

Phil and Penny Knight

They are the primary benefactors who provided a $2 billion commitment to the organization.

Oregon Health & Science University

This is the parent academic health center that established the self-governing Knight Cancer Group.

The details

The Knight Cancer Group manages the care delivery model and operational oversight for the Knight Cancer Institute in Portland. The leadership team includes President Brian Druker, CEO Joel Helmke, and a range of functional chiefs covering finance, human resources, experience, transformation, and nursing.

August 2025: OHSU established the Knight Cancer Group.
June 2026: The OHSU board approved the group as a self-governing nonprofit.
September 24, 2026: The board and executive leadership team were officially announced.

Market Landscape

This move mirrors the Dana-Farber Cancer Institute organizational model, reflecting a broader trend of top-tier medical centers spinning off cancer services into autonomous entities. By centralizing leadership, the group aims to increase operational efficiency compared to traditional university departments.

Patients and stakeholders can expect a shift toward more unified oversight of cancer services in Portland. This leadership transition ultimately aims to streamline the delivery of complex care and research outputs at OHSU.

The takeaway

The formalization of this leadership board marks a critical step in the institutional evolution of Portland's cancer care. Patients should note that while administrative governance is changing, the clinical mission of the institute remains focused on advanced oncology services.